Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Clinicopathologic Conference, Adenovirus Meningoencephalitis
NEJM 381:1459-1470, Case 31-2019, 2019
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Clinical Pathologic Conference, West Nile Virus Encephalitis
NEJM 377:1878-1886, Case 34-2017, 2017
Herpes Simplex Encephalitis in an Immunocompromised Adult with Novel MRI and Pathology Findings
Clin Neuroradiol DOI: 10.1007/s00062-016-0536-x, Modak, J.,et al, 2016
Disseminated Varicella Zoster Virus Encephalitis
Lancet 384:1698, Chai, W. & Gong-Ruey Ho, M., 2014
Human Herpes 6 Virus Encephalitis Complicating Allogeneic Hematopoietic Stem Cell Transplantation
Neurol 80:1494-1500, Bhanushali, M.,et al, 2013
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised
Neurol 79:2125-2132, Tan, L.,et al, 2012
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Atypical Herpes Simplex Virus Encephalitis Diagnosed by PCR Amplification of Viral DNA from CSF
Neurol 51:554-559, Fodork,P.A.,et al, 1998
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Progressive Quadriparesis and Falls in a 66-Year-Old Man With Longstanding Human Immunodeficiency Virus
Neurol 106:e214621, Ong,B.A. & Carlson,A.K., 2026
Clinicopathological Conference, Powasan Virus Encephalitis
NEJM 393:176-184, Case 19-2025, 2025
Clinicopathologic Conference, HIV Type 2 Infection & Cerebral Toxoplasmosis
NEJM 383:859-866, Case 27-2020, 2020
A Patient with a History of Weight Loss Presenting with Seizures
Neurol 95:e2038-e2042, Tang, G. & Benavides, D.R., 2020
Clinicopathologic Conference, Borrelia Miyamotoi Infection
NEJM 383:1578-1586, Case 32-2020, 2020
A 73-Year-Old Man with Recurrent Aphasia, Headaches, and Confusion
Neurol 95:e2595-e2599, Bose, G.,et al, 2020
A 52-year-old woman with a 3 weeks of progressive gait ataxia and dysarthria
Neurol 90:e985-e989, Ly, C.,et al, 2018
Clinicopathologic Conference, Granulomatous Amebic Encephalitis and Sarcoidosis (Inactive)
NEJM 376:368-379, Case 3-2017, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Rapid Multifocal Neurologic Decline in an Immunocompromised Patient
JAMA Neurol 73:226-231, Kromm, J.A.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Magnetic Resonance Imaging of Cerebral Aspergillosis: Imaging and Pathological Correlations
PLoS ONE 11:DOI:10.1371/Journal.pone.0152474, Marzoif, G.,et al, 2016
Chronic Herpes Simplex Type-1 Encephalitis with Intractable Epilepsy in an Immunosuppressed Patient
Infection 44:121-125, Laohathai, C.,et al, 2016
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Cryptococcal Meningoencephalitis in a Patient with Multiple Sclerosis Treated with Fingolimod
JAMA Neurol 72:1203-1205, Zhan, Y.,et al, 2015
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Progressive Multifocal Leukoencephalopathy
Adams & Victors Principles of Neurology, Chp 33, pg 767, Ropper, A.H.,et al, 2014
Aspergillus Meningitis: A Rare Clinical Manifestation of Central Nervous System Aspergillosis
J Infect 66:218-238, Antinori, S.,et al, 2013
Meningoencephalitis from Borrelia Miyamotoi in an Immunocompromised Patient
NEJM 368:240-245, Gugliotta, J.L.,et al, 2013
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Diagnostic Role of Target Lesion on Diffusion-WEighted Imaging, A Case of Cerebral Aspergillosis and Review of the Literature
Neurologist 16:364-367, Finelli,P.F.,et al, 2010
Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Clinicopath Conf., Ruptured Mycotic Aneurysms of Basilar Artery Due to Aspergillosis of Sphenoid Sinuses and Optic Nerve Infarction
NEJM 358:2619-2628, Case 18-2008, 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Post-Transplant Acute Limbic Encephalitis: Clinical Features and Relationship to HHV6
Neurol 69:156-165, Seeley,W.W.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005